KLOW

KLOW is a blend researchers use for skin regeneration, anti-inflammatory effects, and general tissue healing and recovery: it combines four peptides in one vial, GHK-cu (a copper-tripeptide, the largest share, for collagen and skin), BPC-157 (for connective-tissue repair and blood-vessel growth), TB-500 (for cell migration and tissue remodeling), and KPV (for reducing inflammation). It is not an FDA-approved product, and the four-component combination has never been studied in clinical trials, so the blend's effect rests on each component's separate, individually limited evidence plus research-community experience, not proof that combining them adds benefit.

KLOW is marketed for skin regeneration, anti-inflammatory effects, and general recovery, as a fixed four-component blend. It has never been studied as a combination in clinical trials (no published study or registered trial of the four-component combination has been found), so there is no randomized evidence for the blend itself. Its rationale rests on the separate, individually limited evidence bases of its components plus research-community experience, so the combined effect should be read as unproven.

Not FDA approved as a blend (KLOW is a compounded research-peptide formulation; no FDA-approved KLOW product exists). Components have varying individual regulatory status (see component cross-references). Not listed as a blend in the WADA 2026 Prohibited List, but two of the four components are WADA-prohibited: BPC-157 is listed under S0 (Non-Approved Substances), prohibited at all times and explicitly named; TB-500 (thymosin β4 derivatives) is listed under S2.3 (Growth Factors and Growth Factor Modulators). BPC-157's S0 status is the most restrictive designation in the blend. FDA 503A status (current as of 2026-09-03): no component carries a live Category 2 designation — GHK-cu's nomination was withdrawn ~April 15, 2026 and BPC-157 was removed from Category 2 ~April 22, 2026; three of the four components (BPC-157, TB-500, KPV) were voted on at the FDA Pharmacy Compounding Advisory Committee (PCAC) 503A Bulks List meeting held July 23, 2026 (FDA's briefing document proposed against including any of them), while GHK-cu sits on a separate PCAC track expected before the end of February 2027. FDA has published no summary minutes, vote results, or determination from that meeting as of 2026-09-03, and a PCAC recommendation is advisory and non-binding. No component is on the 503A Bulks List, so the most-restrictive-component rule still yields: the blend is not compoundable under 503A. Researchers competing in WADA-tested sport should treat KLOW as containing prohibited components and should not use it.

KLOW is a compounded blend with no FDA-approved product. Two components (BPC-157 and TB-500) are prohibited in WADA-tested sport, so athletes should not use it. Its US compounding status is unsettled: three of the four components (BPC-157, TB-500, KPV) are under FDA 503A Bulks List review at the July 23–24, 2026 advisory-committee meeting with no FDA determination published as of 2026-09-03, and GHK-cu's nomination was withdrawn in April 2026. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. KLOW is a compounded research-peptide blend; no FDA-approved KLOW product exists. Information in this entry is informational, not medical advice. Always confirm dose calculations and consult appropriate professional guidance before any protocol decisions.

⚠️ Composition reflects the most-cited research-community KLOW formulation ( total per vial). The canonical KLOW blend formulation referenced across multiple research-peptide vendors and compounding-pharmacy sources is: GHK-cu + BPC-157 + TB-500 + KPV = total per vial. Some KLOW formulations vary (different total weights, different ratios, occasional component substitutions). Researchers should confirm the specific formulation of their actual product against the vial label and Certificate of Analysis before using this entry's dosing math — vendor formulations are not standardized and the rationale below assumes the canonical ratio. Component cross-references: [GHK-cu](./ghk-cu.md), [BPC-157](./bpc-157.md), [TB-500](./tb-500.md), [KPV](./kpv.md).

⚠️ Mismatched-range blend — the dose ratio is fixed at vial-formulation but components have substantially different typical research-community dose ranges. Per the blend taxonomy established for the BPC-157/TB-500 blend entry, KLOW is a mismatched-range blend — the four components have meaningfully different typical research-community dose ranges in their standalone use (GHK-cu typically; BPC-157 typically; TB-500 typically; KPV typically). At the canonical per-vial ratio, dosing decisions for KLOW require accepting that at least some component will be outside its standalone "ideal" research-community range at any given total-blend dose. Researchers should be explicit with themselves about which component they are prioritizing dosing-wise.

⚠️ No FDA-approved or published-RCT-validated dosing protocol for KLOW. Like all blend entries in the library, KLOW lacks RCT-grade evidence at any specific dose. The patterns reflect research-community-attributed practice. This is the third blend entry in the library; the [BPC-157/TB-500 blend](./bpc-157-tb-500-blend.md) and [CJC-1295/Ipamorelin blend](./cjc-1295-ipamorelin-blend.md) entries cover analogous frameworks for two-component blends.

⚠️ Component-level WADA and FDA caveats compound across the blend. Two components are WADA-prohibited: BPC-157 under S0 (Non-Approved Substances, prohibited at all times, explicitly named — the most restrictive status in the blend) and TB-500 (a thymosin β4 derivative) under S2.3 (Growth Factors). On the FDA side, no component now carries a live 503A Category 2 designation — GHK-cu's nomination was withdrawn ~April 15, 2026 and BPC-157 was removed from Category 2 ~April 22, 2026 — but three of the four components (BPC-157, TB-500, KPV) were on the FDA pcac 503A Bulks List docket for July 23–24, 2026 and were voted on at that meeting; FDA has published no minutes, vote results, or determination as of 2026-09-03. Removal from Category 2 does not mean these components are approved or straightforwardly compoundable. KLOW therefore inherits these regulatory complications: it should not be used by athletes in WADA-tested sport, and its US compounding-pharmacy supply path remains unsettled pending the July 2026 advisory-committee outcome. Confirm the final PCAC determinations — FDA had published no minutes, vote results, or determination as of 2026-09-03; re-check before App Store submission.

KLOW is a research-community compounded peptide blend combining four research peptides into a single lyophilized formulation marketed for tissue regeneration, anti-inflammatory effects, and broad healing/recovery indications. The canonical formulation across multiple research-peptide vendors and compounding-pharmacy sources contains: GHK-cu (the largest component), BPC-157, TB-500, and KPV — for a total lyophilized peptide per vial.

Component-level rationale: - GHK-cu (the largest component) — copper-tripeptide complex; primary contributor to the blend's wound-healing, collagen-synthesis, and anti-aging skin effects.[¹] - BPC-157 — gastric-juice-derived peptide fragment; primary contributor to the blend's gut-healing, tendon/ligament-repair, and angiogenesis-promoting effects. - TB-500 — thymosin β4-derived fragment; primary contributor to the blend's cell-migration and tissue-remodeling effects. - KPV — α-MSH-derived tripeptide; primary contributor to the blend's anti-inflammatory effects (NF-κB and MAP kinase pathway inhibition via PepT1).

Mechanism — multimodal complementary action. The KLOW formulation rationale is that the four components target distinct but complementary aspects of tissue healing and inflammation: - GHK-cu drives collagen synthesis and gene-expression modulation supporting tissue regeneration. - BPC-157 promotes angiogenesis and tendon/ligament repair. - TB-500 supports cell migration during tissue remodeling. - KPV reduces inflammatory cytokine production via NF-κB inhibition.

The combined effect is theoretically broader than any single component and is the marketing rationale for the blend formulation. The combined effect is not characterized in published clinical literature — KLOW has not been studied as a fixed combination in RCTs; the evidence base is the union of the four components' individual evidence bases (each thin) plus accumulated research-community experience.

Common research interests. KLOW's research-community use spans: - Tissue regeneration / injury recovery — the dominant rationale, leveraging the multi-mechanism healing approach - Inflammatory conditions — KPV's anti-inflammatory contribution combined with GHK-cu and BPC-157's tissue-repair effects - Skin and connective tissue (anti-aging) — driven primarily by the GHK-cu component - Athletic recovery — the four components' combined healing/regeneration rationale

Regulatory status (current as of 2026-09-03). No FDA-approved KLOW product exists. The blend's regulatory status inherits from its components, and every component's status moved in 2026 — no component now carries a live FDA 503A Category 2 designation: - GHK-cu: legal as a topical cosmetic ingredient in the US; injectable 503A bulks-list nomination withdrawn ~April 15, 2026 and removed from its prior category → transitional / gray-area status, with a PCAC consultation planned before the end of February 2027. Not WADA-listed by name. - BPC-157: removed from Category 2 ~April 22, 2026; was voted on at the FDA pcac 503A Bulks List meeting held July 23, 2026, with FDA's briefing document proposing against adding it. FDA has published no minutes, vote results, or determination as of 2026-09-03, and a PCAC recommendation is advisory and non-binding, so 503A compounding is not permitted on that basis. WADA S0 (Non-Approved Substances, prohibited at all times, explicitly named). - TB-500: previously Category 2, removed spring 2026; a named subject of the PCAC 503A Bulks List review and voted on at the meeting held July 23, 2026, FDA proposing against adding it. FDA has published no minutes, vote results, or determination as of 2026-09-03, and a PCAC recommendation is advisory and non-binding, so 503A compounding is not permitted on that basis. WADA S2.3 listed (Growth Factors). - KPV: (free base and acetate) were on the PCAC agenda for the 503A Bulks List under "wound healing and inflammatory conditions" and were voted on at the meeting held July 23, 2026; FDA has published no minutes, vote results, or determination as of 2026-09-03, and a PCAC recommendation is advisory and non-binding, so 503A compounding is not permitted on that basis. public docket includes FDA-2025-N-6895. Not WADA-listed by name, though the S0 (non-approved substance) default applies since it holds no regulatory approval anywhere.

None of the four components is DEA-scheduled.

The combined effect: KLOW contains two WADA-prohibited components (BPC-157 S0 + TB-500 S2.3), and three of its four components are under FDA 503A Bulks List review on July 23–24, 2026. Researchers in WADA-tested sport should not use KLOW — BPC-157's S0 listing, prohibited at all times, is the most restrictive status in the blend. US researchers should be aware that removal from Category 2 does not mean these components are approved or straightforwardly compoundable; the US compounding-pharmacy supply path for KLOW remains unsettled pending the July 2026 advisory-committee determinations and the GHK-cu consultation expected before the end of February 2027. Confirm the final PCAC determinations — FDA had published no minutes, vote results, or determination as of 2026-09-03; re-check before App Store submission.

Commonly reported

• Combined angiogenic activity. Both BPC-157 and GHK-cu have angiogenic effects; the combined effect may be additive. Theoretical contraindication for active or undiagnosed malignancy applies with multiple components present.
• Injection site reactions — common across all four components.
• Mild flushing or warmth post-injection — uncommon.
• Generally well-tolerated in research-community reports at typical doses.

Active malignancy or undiagnosed cancer concern — caution; multiple components have angiogenic or gene-expression-modulating activity

Wilson disease or copper metabolism disorders — strongly contraindicated due to GHK-cu copper content

Pregnancy and lactation: no data; default to contraindicated

Pediatric use: no data — should not be used in researchers under 18

Active immunosuppressive therapy — caution; KPV's anti-inflammatory activity may be additive to immunosuppression

Regulatory note (US, as of 2026-09-03): no KLOW component carries a live FDA 503A Category 2 designation — GHK-cu's nomination was withdrawn ~April 15, 2026 and BPC-157 was removed ~April 22, 2026 — but three of the four components (BPC-157, TB-500, KPV) were voted on at the FDA pcac 503A Bulks List meeting held July 23, 2026, and FDA's briefing document proposed against including any of them. FDA has published no summary minutes, vote results, or final determination from that meeting as of 2026-09-03, and a PCAC recommendation is advisory and non-binding — panel review → FDA determination still pending → 503A compounding not permitted on that basis, and no component is on the 503A Bulks List — so the most-restrictive-component rule still yields a non-compoundable blend. Removal from Category 2 does not imply approval or that compounding is now permitted.

Regulatory note (WADA): two components are prohibited — BPC-157 under S0 (Non-Approved Substances, prohibited at all times, explicitly named) and TB-500 (thymosin β4 derivatives) under S2.3 (Growth Factors). Researchers in WADA-tested sport should not use KLOW.

Peptide blend

A combination of two or more peptides prepared together in a single formulation.

Peptide

A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.

Subcutaneous

An injection into the fatty layer just under the skin, rather than into a muscle or vein.

Compounding pharmacy

a pharmacy that prepares a medication to order under a prescription.

1. Component-level citations apply via the cross-referenced standalone entries: GHK-cu, BPC-157, TB-500, KPV. The KLOW blend itself has not been studied as a fixed combination in published RCTs; this entry's citations are inherited from the component standalone entries.
2. Research-community vendor formulation references — KLOW is sold by multiple research-peptide vendors with the canonical formulation (PeptideSciences, BioLongevityLabs, AlphaBioMed, others). Vendor formulations should be confirmed against the specific product Certificate of Analysis.
3. WADA listings for component peptides — KLOW inherits WADA-prohibited status via two components: BPC-157 under S0 (Non-Approved Substances, prohibited at all times, explicitly named in the List text) and TB-500 / thymosin β4 derivatives under S2.3 (Growth Factors and Growth Factor Modulators) of the 2026 Prohibited List. See the BPC-157 entry for the canonical S0 citation and the TB-500 entry for the canonical S2.3 citation.
4. FDA 503A bulks list status of the components — materially changed in 2026; no component carries a live Category 2 designation. GHK-cu: 503A nomination withdrawn ~April 15, 2026 and removed from its prior category → transitional/gray-area, with a PCAC consultation planned before the end of February 2027. BPC-157: removed from Category 2 ~April 22, 2026. Three of the four components — BPC-157, TB-500, and KPV — are on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for July 23–24, 2026 for the 503A Bulks List; FDA briefing materials propose against adding BPC-157 and TB-500, and KPV (free base and acetate) is agendaed under "wound healing and inflammatory conditions" — all determinations pending. Public docket includes FDA-2025-N-6895 (KPV). See the GHK-cu, BPC-157, TB-500, and KPV entries, which carry the primary FDA agenda and briefing-document citations. Removal from Category 2 does not mean a component is approved or straightforwardly compoundable; KLOW's US compounding-pharmacy supply path remains unsettled.

• CJC-1295 — discussed together in this entry's stacks section
• Tesamorelin — discussed together in this entry's stacks section
• NAD+ — discussed together in this entry's stacks section
• ARA-290 — same mechanism class
• BPC-157 / TB-500 Blend — same mechanism class
• BPC-157 — same mechanism class